New Medications Released During 2005
Instructions:
ATT: Elizabeth A Huss
HBC, HPI 4th Floor
Fax: 512-223-7030
Date:
First Name: Last
Name:
Post-Test: New medication Released During 2005
1. Where was the anti-diabetic drug Byetta (exenatide) isolated from?
a. Byetta was not isolated: it was created in the laboratory.
b. The venom of the Gila Monster, which “turns the pancreas on” was used to isolate Byetta.
c. The woodchuck was used to isolate the active ingredient of Byetta.
d. Foxglove was used to isolate this anti-diabetic drug.
2. The first non-insulin therapy available for Type I diabetes mellitus is:
a. Byetta (exenatide)
b. Levemir (insulin detemir)
c. Symlin (pramlintide acetate)
d. Rozerem (ramelteon)
3. The first subcutaneous medication for Type II diabetes is:
a. Byetta (exenatide)
b. Levemir (insulin detemir)
c. Symlin (pramlintide acetate
d. Rozerem (ramelteon)
4. A long acting insulin analog with a 24 hour durations is:
a. Regular insulin
b. Starlix (nateglinide)
c. Humalog (insulin lispro)
d. Levemir (insulin detemir)
5. Tygacil (tigecycline) a new antibiotic from the Tetracycline family has all of the following nursing considerations but:
a. Caution the patient if on birth control as Tygacil neutralized birth control medication.
b. Warn the patient to avoid direct sunlight as Tygacil may cause skin sensitivity.
c. Encourage the patient to take drug with milk or milk products to prevent gastric irritation.
d. Drug in the Tetracycline family may discolor teeth in the unborn child.
6. Which anti-carcinogenic drug for breast cancer is combined with Human Albumin to shoren infusion time and decrease side effects?
a. Arronon (nelarabine)
b. Abraxane (paclitaxel)
c. Nexavar (sorafenib)
d. Revlimid (lenalidomide)
7. the rationale for the development of new biologics is:
a. Vaccines are combined to decrease number of injections needed
b. Conjugated vaccines produce better efficacy
c. Vaccines are given to eradicate contagious diseases now and in the future.
d. All of the above
New Medications Released During 2005 Evaluation:
Legend:
1 = Strongly Disagree
2 = Mildly disagree
3 = Neutral
4 = Mildly Agree
5 = Strongly Agree
1. The following objectives were met.
a. Identify the trade or generic name, classification, dosage/delivery fact or nursing action/safety precaution that you will take during administration of each or the new drugs that have appeared on the market during the year of 2005.
1 2 3 4 5
b. Identify characteristics of the three (3) new drugs for diabetes as it affects administration.
1 2 3 4 5
c. Identify administration facts for the new cancer drugs.
1 2 3 4 5
d. State the rational for the development of new biologicals.
1 2 3 4 5
2. Guest Speaker- Renee Acosta, RPh
a. Knowledge and currency of topic.
1 2 3 4 5
b. Ability to make points clear.
1 2 3 4 5
c. Ability to apply content to practice.
1 2 3 4 5
d. Speaking style.
1 2 3 4 5
3. Moderator- Elizabeth Huss, RN, BS, BSN
a. Guides the discussion.
1 2 3 4 5
b. Asks pertinent questions.
1 2 3 4 5
c. Encourages attention to subject matter.
1 2 3 4 5
d. Fosters clarification of presented information.
1 2 3 4 5
e. Fosters relaxed attentiveness
1 2 3 4 5
How much time did it take you to watch the video? _______Minutes
How much time did it take you to complete the posttest? _______Minutes